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ABSTRACT Despite success in reducing vertical HIV transmission by maternal anti-
retroviral therapy, several obstacles limit its efficacy during breastfeeding, and
breast-milk transmission is now the dominant mode of mother-to-child transmission
(MTCT) of HIV in infants. Thus, a pediatric vaccine is needed to eradicate oral HIV in-
fections in newborns and infants. Utilizing the infant rhesus macaque model, we
compared 3 different vaccine regimens: (i) HIV envelope (Env) protein only, (ii) pox-
virus vector (modified vaccinia virus Ankara [MVA])-HIV Env prime and HIV Env
boost, and (iii) coadministration of HIV Env and MVA-HIV Env at all time points. The
vaccines were administered with an accelerated, 3-week-interval regimen starting at
birth for early induction of highly functional HIV Env-specific antibodies. We also
tested whether an extended, 6-week immunization interval using the same vaccine
regimen as in the coadministration group would enhance the quality of antibody re-
sponses. We found that pediatric HIV vaccines administered at birth are effective in
inducing HIV Env-specific plasma IgG. The vaccine regimen consisting of only HIV
Env protein induced the highest levels of variable region 1 and 2 (V1V2)-specific an-
tibodies and tier 1 neutralizing antibodies, whereas the extended-interval regimen
induced both persistent Env-specific systemic IgG and mucosal IgA responses. Antibody-
dependent cell-mediated cytotoxicity (ADCC) antibodies in plasma were elicited by all
vaccine regimens. These data suggest that infant immunizations beginning at birth are
effective for the induction of functional HIV Env-specific antibodies that could potentially
protect against breast milk transmission of HIV and set the stage for immunity prior to
sexual debut.
KEYWORDS HIV vaccine, antibody responses, infant rhesus macaque model
In industrialized nations, mother-to-child transmission (MTCT) of human immunode-ficiency virus (HIV) has been virtually eliminated by prenatal screening, the use of
antiretroviral therapy (ART), and avoidance of breast feeding. Despite major progress,
access to these MTCT prevention strategies remains highly variable in many resource-
limited countries. Global ART coverage for prevention of MTCT (PMTCT) was estimated
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at 80% in 2015. This coverage was 90% in East and Southern Africa but remained
below 50% in Asia and many other regions in Africa (1). In addition, HIV infection rates
in women aged 15 to 24 only declined by 6% between 2005 and 2015 (2). Women
experiencing acute HIV infection, especially late in pregnancy and/or during the
breastfeeding period, are most likely to transmit infection to their babies (3). Even when
mothers are diagnosed with HIV and started on ART during the breastfeeding period,
the risk of MTCT remains high due to poor maternal adherence (4–6). Thus, in 2015,
150,000 infants (400 infants per day) became newly infected with HIV, half by
breastfeeding (7, 8). Because breastfeeding is essential to provide nutrients and passive
immunity against other pathogens that are prevalent in resource-poor countries, novel
strategies are critically needed to eliminate breast milk transmission of HIV.
Ideally, a pediatric HIV vaccine would prevent breastfeeding infants born to HIV-
infected women from becoming infected. Protection would have to be elicited rapidly
in the face of continual exposures starting early after birth. Recent studies showed that
HIV-infected infants could rapidly develop broadly neutralizing antibodies (9, 10),
suggesting that despite their less mature immune system, infants can generate potent
immune responses. However, the development of HIV immunogens that induce high
titers of broadly neutralizing antibodies has proved challenging. In contrast, nonneu-
tralizing antibodies with FcR-mediated effector functions are easier to induce by
vaccination. In addition, in the immune correlates analysis of the RV144 adult HIV
vaccine trial, low levels of plasma antibodies that mediated antibody-dependent cell-
mediated cytotoxicity (ADCC) were identified as a correlate of risk (11–16).
Simian immunodeficiency virus (SIV) infection of rhesus macaques (Macaca mulatta)
is the most relevant animal model for the study of HIV pathogenesis and vaccine
testing. All modes of MTCT of HIV (in utero, peripartum, and through breast milk) can
be recapitulated in the SIV macaque model (17, 18), and immune development is
similar in infant macaques and humans. Our goal was to identify a vaccine regimen that
induces high-magnitude, persistent, ADCC-mediating, HIV Env-specific antibodies.
Based on prior observations, we selected 4 immunization regimens consisting of
2 immunogens, an HIV envelope (Env) protein and a poxvirus vector, which were
administered on either an accelerated or extended time schedule. We utilized an Env
protein immunogen because gp120 proteins delivered with adjuvant elicited long-
lasting antibody responses in human infants (19). We selected HIV C.1086 Env derived
from an HIV clade C transmitted founder virus because clade C is the most prevalent
clade in sub-Saharan Africa, where the majority of pediatric HIV infections occur. In
addition to the intramuscular (i.m.) route, C.1086 Env was also administered by the
intranasal (i.n.) route to induce mucosal IgA, since breast milk acquisition of HIV occurs
via mucosae. Indeed, prior pediatric SIV vaccine studies suggested that vaccine-induced
mucosal IgA at the time of challenge correlated with control of viremia (20). The
modified vaccinia virus Ankara (MVA) poxvirus vector expressing viral proteins was
selected because of the modest protection with another poxvirus vector (canarypox) in
the RV144 trial (21), the excellent safety record of poxviruses in human infants (22–25),
and our previous demonstration that poxvirus-based vaccines elicited partial protection
against oral SIV challenge in infant rhesus macaques (23). Finally, we compared an
accelerated versus an extended-interval vaccination regimen because, while rapid
elicitation of immune responses is needed, age-related changes in the developing
infant immune system could improve the quantity and quality of vaccine-induced
antibodies.
Four groups of infant macaques were used to test the immunogenicity of the
different vaccine regimens. Three of these regimens (Env protein, prime/boost, and
coadministration) were accelerated (3 immunizations at 3-week intervals), with the 4th
group (extended interval) receiving the same regimen as the coadministration group
but at 6-week intervals. The results are presented by comparing the 3 accelerated
regimens, followed by a comparison of the accelerated and extended-interval coad-
ministration groups. Our data show that the Env protein vaccination group elicited
higher-avidity plasma IgG, the fastest kinetics of tier 1 neutralization, and the strongest
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variable region 1 and 2 (V1V2)-specific antibodies among the accelerated vaccine
regimens. Yet, the extended-interval vaccine regimen was the only strategy that
resulted in the development of both systemic IgG and mucosal IgA HIV Env-specific
antibody responses, and it elicited tier 1 neutralizing and V1V2-specific antibodies
similarly to the Env protein regimen.
RESULTS
HIV Env-specific plasma IgG responses. Figure 1 provides an overview of the
study outline with the various vaccine regimens. The kinetics of gp120-specific plasma
IgG development using the 3 accelerated vaccine regimens are illustrated in Fig. 2A. All
groups, with the exception of the prime/boost group, began to produce IgG to
consensus C gp120 after the first vaccination with C.1086 gp120 (Fig. 2A). The prime/
boost group had detectable antibody responses after the second vaccination. Antibody
responses to consensus C gp120 peaked 2 weeks after the third and final immunization
in all accelerated vaccine cohorts and were of similar magnitudes at peak and there-
after. At euthanasia (week 15 for the prime/boost and coadministration groups and
week 19 for the Env protein group), the gp120-specific IgG concentrations had de-
creased 10-fold in all 3 groups (Fig. 2A).
We further tested whether this subtype C vaccine elicited Env-specific IgG that
recognized different clades. All regimens induced plasma IgG that bound to clade A
gp140, clade B gp140, and clade E gp120 (Fig. 2B). The responses to clade B gp140 were
more variable than the other responses within most groups. Additionally, in relation to
the levels of binding to clade C gp120, the median response to clade E gp120 was
reduced by approximately a half log in the prime/boost group (Fig. 2B).
Epitope breadth of vaccine-induced plasma IgG. Antibodies elicited in the hu-
man RV144 HIV vaccine trial mediated ADCC, and responses specifically targeted V1V2
(15, 26), the third variable loop (V3) (27), and the first constant domain (C1) (14).
Antibodies specific for the V2 epitope correlated with a decreased risk of HIV infection
in these vaccinated adults (15). However, protection of human infants against vertical
HIV transmission has been associated with maternal antibodies directed against the V3
loop (28). Using a binding antibody multiplex assay (BAMA), we found that peak plasma
IgG responses to the C1, V2, and V3 epitopes of the C.1086 gp120 immunogen did not
differ between groups (Fig. 2C). However, infants in the Env protein group had higher
FIG 1 Vaccine regimens. Shown are the 4 vaccination groups and immunogens administered by the i.m.
and i.n. routes. The timeline is expressed in weeks according to infant macaque age. Immunizations are
indicated by symbols. Vaccine doses are listed at the bottom of the figure. Nx, necropsy.
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levels of plasma IgG against the V1V2 epitope than did the prime/boost group (P 
0.02) (Fig. 2C and Table S1 in the supplemental material).
Consistent with these BAMA data, the results from linear peptide array mapping
showed that all groups recognized epitopes of other virus clades (Fig. 2D), and the
FIG 2 HIV Env-specific plasma IgG. (A) HIV gp120 consensus C-specific plasma IgG concentrations over time, measured by ELISA, are shown as mean values 
standard errors of the means (SEM). Arrows indicate the times of immunization. The dashed line represents the cutoff for HIV Env-specific IgG concentrations
considered positive above the background. (B) Log10 MFI values for plasma IgG specific for clade A or clade B gp140 and clade E and clade C gp120 at peak
(week 8, equal to 2 weeks after the 3rd immunization) that were measured by BAMA. (C) Specificities of clade C Env-specific plasma IgG determined at week
8 using BAMA. (D) Pie chart illustrating median signal intensities of IgG that recognize Env proteins from different clades by linear epitope mapping. (E) Pie
chart summarizing results of linear epitope mapping of plasma IgG at week 8. Note that we did not perform linear epitope mapping for the prime/boost group
because they showed slightly delayed induction of gp120-specific plasma IgG and generally had lower responses in the BAMA assay.
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majority of antibodies at the peak of the vaccine phase (2 weeks after the last
immunization) targeted clade C V3 epitopes. However, we also detected antibodies
against epitopes in the C1, V2, C2, V3, C3, V4, V5-C5, and C5 regions of Env (Fig. 2E and
Table S2).
Effect of extending the time interval between immunizations on HIV Env-specific
plasma IgG responses. Rationalizing that an increased interval between immunizations
might allow for greater immune maturation and improved antibody responses, we
compared the Env-specific antibody responses in the accelerated 3-week-interval co-
administration group to the responses in the 6-week extended-interval coadministra-
tion group. Animals in both groups produced consensus C gp120-specific plasma IgG
2 weeks after the first immunization (Fig. 3A). Peak Env-specific IgG in the extended-
interval group were observed 2 weeks after the last immunization (week 14), similar to
what was seen in the coadministration group at week 8 (Fig. 3A). No evidence was
FIG 3 Env-specific antibody responses induced by the extended-interval regimen. (A) Comparison of mean consensus C gp120-specific plasma IgG
concentrations in the 3-week accelerated coadministration group and 6-week extended-interval group. Black and red arrows indicate the times when
immunizations were performed in the coadministration and extended-interval groups, respectively. (B) Median frequencies of plasmablasts in bone marrow of
vaccinated animals at the time of euthanasia. Plasmablast frequencies are reported as percentages of Ki-67 ICIgG cells within the CD20/int population. (C)
Pie charts illustrating the median relative signal intensities of Env proteins of other clades or clade C Env epitopes recognized at weeks 8 and 15 by plasma
IgG in animals of the extended-interval group as determined by linear epitope mapping. (D) Specific activities of C.1086 gp120-specific IgA, expressed as
nanograms of anti-gp120 IgA per g of total IgA, in fecal extracts prepared from stool samples. The dotted line indicates the cutoff for samples considered
to be positive for C.1086 gp120-specific IgA.
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found of peak Env-specific IgG concentrations differing between groups (P 0.31). The
gp120-specific plasma IgG concentrations in the extended-interval group declined
slightly after week 14, but these levels stabilized by week 20 and were maintained until
week 32, suggesting that long-lived Env-specific plasma cells were generated. An
additional boost at week 32 increased gp120-specific IgG to the levels observed at the
time of peak response (Fig. 3A), indicating that gp120-specific memory B cells were also
generated by the 6-week vaccination regimen. To confirm the generation of long-lived
plasmablasts, we measured the frequencies of Ki-67-positive (Ki-67) B cells with no or
only intermediate expression of CD20 (CD20/int) that tested positive for intracellular
IgG but did not express surface IgG in bone marrow (Fig. 3B). The median plasmablast
frequency in the bone marrow of animals receiving the accelerated coadministration
regimen (0.26%) was higher than that observed in the Env protein-only (0.06%) or
prime/boost (0.10%) group, but there was great variability within each group; the
median plasmablast frequencies were similar between animals in the accelerated and
extended-interval (0.19%) coadministration groups (Fig. 3B).
To further compare the specificities, magnitudes, and breadths of linear epitope
binding between the coadministration and extended-interval groups, we mapped
plasma antibodies at weeks 8 and 15 using a linear peptide array. The V3 epitope
dominated the binding responses at week 8 in the extended-interval group (Fig. 3C)
similarly to what was observed in the coadministration group (Fig. 2E). Although V3
responses still represented the dominant response by week 15, responses to C1 and C5
had increased (Fig. 3C). Cross-clade responses were detected to similar extents at both
time points in the extended-interval group, with slight increases in anti-clade C
consensus and clade AG IgG between weeks 8 and 15 (Fig. 3C). At week 15, cross-clade
responses in the extended-interval group were comparable to those observed at week
8 in the coadministration group (Fig. 2D and E).
Induction of HIV Env-specific mucosal antibodies and B cell responses. The
orogastrointestinal tract is an entry site for virus in breast milk. In previous studies, we
found that vaccine-induced Env-specific IgA in saliva and intestinal secretions was
associated with control of viremia in orally infected infant macaques (20, 29). Thus, an
effective pediatric HIV vaccine may depend on the induction of local, mucosal IgA
responses at the entry sites. Although we administered gp120 protein by both the i.m.
and i.n. routes, the levels of C.1086 gp120-specific IgG and IgA were low or undetect-
able in saliva and did not differ between groups at the peak of the vaccine phase (data
not shown). Similarly, the median values of gp120-specific IgA in stool samples from the
Env protein, prime/boost, and coadministration vaccine groups were below the thresh-
old for positivity. In contrast, all animals in the extended-interval group had low but
detectable levels of gp120-specific IgA in their stool samples, indicating that an
intestinal IgA response had been generated (Fig. 3D).
Avidity of vaccine-elicited anti-gp120 IgG. In previous SIV or simian-human
immunodeficiency virus (SHIV) vaccine studies with adult macaques, the avidity of
anti-Env serum IgG, as measured by chaotropic sodium thiocyanate (NaSCN) displace-
ment enzyme-linked immunosorbent assay (ELISA), has been correlated with protection
(30, 31). In these assays, antibody avidity has been reported as the avidity index (AI),
and antibodies with an AI of 30, 30 to 50, or 50 have been considered to be of low,
intermediate or high avidity, respectively (32). In the current study, the median AI
values of C.1086 gp120-specific plasma IgG at peak (2 weeks after the third immuni-
zation) were in the low range for animals in the prime/boost (AI  24) and Env protein
(AI 27) groups, whereas animals in the coadministration group developed antibodies
with intermediate avidity (AI  37) (Fig. 4A). The extended-interval coadministration
regimen induced antibodies with the highest avidity (AI  47) (Fig. 4A).
We also measured antibody avidity using surface plasmon resonance (SPR), which
may more accurately measure avidity to conformational epitopes. Using SPR, the
median avidity score of C.1086 gp120-specific antibodies was found to be higher in the
Env protein group than in the prime/boost and coadministration groups (Fig. 4B).
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FIG 4 Plasma IgG avidity at the time of peak responses. (A) The avidity index for C.1086 gp120-specific IgG in
plasma of animals within each vaccine regimen at peak was measured using the NaSCN displacement ELISA. (B) The
avidity score, determined by SPR, is shown for each animal at peak. (C and D) The differences between the Env
protein and prime/boost groups and between the accelerated and extended-interval coadministration groups for
IgG avidity scores to clade C CH505 gp120 (C) and group M Con-S A11 gp120 (D) are illustrated. (E and F) The
respective maximum binding responses and dissociation rates that determined the C.1086 gp120 avidity scores
presented in panel B are shown. (G and H) The results of Spearman rank tests for the C.1086 gp120 avidity index
and avidity score (G) and for the C.1086 gp120 avidity index and the dissociation rate measured by SPR (H) are
shown. The symbols are as defined in the keys in Fig. 2A and 3A.
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Animals in the Env protein group also had higher avidity scores to clade C CH505 gp120
and the group M Con-S gp120Δ11 protein (Fig. 4C and D). Between the coadministra-
tion regimens, the extended-interval regimen induced antibodies with higher avidity
than the accelerated regimen to C.1086 gp120, CH505 gp120, and M Con-S gp120Δ11
(P  0.01, P  0.03, and P  0.01, respectively) (Fig. 4B to D). The higher avidity of the
C.1086 gp120-specific antibodies in the extended-interval group was attributed to a
very low dissociation rate, as the maximum binding responses did not differ greatly
from those in the coadministration group (Fig. 4E and F).
It is currently unknown which of these avidity assays best predicts protection,
because the results of SPR have not yet been reported for vaccine/challenge studies
with macaques. For this reason, we provide both measurements as a reference point for
both prior and future studies. Although there was no correlation between avidity
indices and avidity scores (Fig. 4G), the avidity indices were inversely correlated with
dissociation rates in the SPR assay (Fig. 4H).
ADCC activity of vaccine-induced HIV Env-specific antibodies. In the RV144 trial,
plasma ADCC activity was inversely correlated with the risk of HIV infection (15). We
measured plasma IgG ADCC activities against the C.1086 gp120 immunogen and
against clade C SHIV1157idp3N4 gp120 2 weeks after the 3rd immunization (week 14
for extended-interval group; week 8 for all others). All regimens induced similar titers
of ADCC-mediating plasma antibodies to C.1086 gp120 (Fig. 5A). In response to
heterologous SHIV1157idp3N4 gp120, the prime/boost group had the lowest ADCC
activity and the extended-interval group the highest (Fig. 5B). We also noted a
correlation between the C.1086 gp120 avidity indices and ADCC activity measured
using SHIV1157ipd3N4 gp120 (Fig. 5C). Thus, the extended-interval regimen elicited the
most consistent ADCC responses against both autologous and heterologous Env
proteins.
Tier 1 virus neutralizing plasma antibodies. We tested the ability of vaccine-
induced antibodies to mediate virus neutralization and found that all vaccination
strategies induced neutralizing antibodies against the tier 1 clade C virus MW965 (Fig.
5D). Neutralizing antibodies were detectable after 2 immunizations (at week 6) in all
infants in the Env protein group and in 4 of 5 infants in the coadministration group.
However, 3 immunizations were required to induce measurable levels of neutralizing
antibodies in all of the prime/boost animals (Fig. 5D). In most animals, peak neutralizing
antibody responses were observed 2 weeks after the third immunization (week 8);
however, in some animals, neutralization titers increased until week 12 (data not
shown). When we compared the maximum titers for each animal, the median peak
neutralizing antibody titer was higher for animals in the Env protein group than for
animals in the prime/boost group (Fig. 5D). None of the three vaccine regimens
induced substantial levels (3-fold above background) of tier 2 autologous neutralizing
antibodies (data not shown).
Similar to our findings for the accelerated vaccine regimens (Fig. 5D), neutralizing
antibodies against the clade C tier 1 virus MW965 peaked 2 weeks after the last
immunization in the extended-interval group (Fig. 5E). Although neutralizing antibody
responses declined, detectable neutralizing antibody persisted and was boosted after
the 4th immunization at week 32 (Fig. 5E). There was a trend (P  0.0952) toward
higher maximum neutralizing antibody responses in the extended-interval group than
in the accelerated coadministration group (Fig. 5E and Table S3).
HIV Env-specific B cells in tissues at time of euthanasia. Next, we investigated
whether differences in gp120-specific IgG levels in plasma and gp120-specific IgA in
stool were reflected by the frequencies of gp120-specific B cells in tissues. We analyzed
spleen samples as a representative systemic lymphoid tissue. Lymph nodes (LNs)
draining the oral cavity (retropharyngeal or submandibular) and intestinal tissues
(colon) were studied, as these tissues represent potential sites of viral entry in infants
orally exposed to virus in breast milk. At necropsy, the coadministration group had the
highest frequencies of HIV Env-specific B cells in the spleen, both in total B cells and the
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FIG 5 ADCC activity and tier 1 neutralizing antibodies in plasma. (A) Plasma was tested for the ability to mediate ADCC against cells coated with the C.1086
gp120 immunogen. Shown are the log10 reciprocal endpoint titers of plasma with detectable ADCC activity for each animal in the four vaccine groups. The
horizontal dashed line represents the cutoff for positivity. Plasma samples from the extended-interval group at week 14 or from the accelerated vaccine
regimen groups at week 8 were tested. The granzyme B activity against C.1086 gp120 cells is expressed as the proportion of target cells positive for
proteolytically active granzyme B out of the total viable target cell population after subtracting the background activity observed in wells containing effector
and target cells in the absence of plasma. (B) The ADCC activities against target cells expressing the heterologous clade C SHIV 1157ipd3N4 gp120 are shown.
(C) Spearman’s rank correlations between the C.1086 gp120 IgG avidity indices and granzyme B activities against SHIV1157ipd3N4 gp120. (D) Development
of plasma IgG that neutralize clade C MW965 infection of TZM-bl cells by 50%. Shown are mean 50% inhibitory concentrations (IC50s)  SD for each of the
vaccine groups (left) and peak IC50 titers of neutralizing plasma antibodies (right) in animals of the accelerated vaccine groups. (E) Comparison of the kinetics
and peak IC50 titers of neutralizing plasma antibodies between the accelerated and extended-interval coadministration vaccine regimens. The symbols are
as defined in the keys in Fig. 2A and 3A.
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memory B cell populations (Fig. 6A). In contrast, the frequency of Env-specific B cells in
oral lymph nodes was highest in the Env protein group (median frequency, 0.91%) and
lowest in the prime/boost group (0.02%) (Fig. 6B). An intermediate frequency was
observed in the coadministration group (0.63%), and this frequency was higher than
that in the prime/boost group (Fig. 6B). These frequencies paralleled those of gp120-
specific CD27 memory B cells (Env protein group, 4.35%; prime/boost group, 0.68%;
and coadministration group, 3.9%) (Fig. 6B). In animals of the extended-interval group,
we analyzed gp120-specific B cells in tissue biopsy specimens at week 15 and at the
time of euthanasia. At week 15, we collected a peripheral LN, because LNs draining the
oral cavity are too deep to be excised from small infant macaques. The median
gp120-specific B cell frequency in the axillary LNs was slightly higher than that
observed in oral LNs (Fig. 6C). At the time of euthanasia, the frequencies of gp120-
specific total and memory B cells in oral LNs were lower in animals receiving the
extended-interval than in those receiving the accelerated coadministration vaccine
regimen, whereas the opposite was observed for the spleen samples (Fig. 6C).
In the colon, gp120-specific B cells were only generated by the extended-interval
regimen (Fig. 6D and E), a finding consistent with the above-described observation that
this regimen was best for the induction of gp120-specific IgA in stool samples.
Env-specific B cells were also found in intestinal biopsy specimens of animals in the
extended-interval group 3 weeks after the 3rd immunization (week 15) (Fig. 6D and E),
the caveat being that antigen-specific intestinal B cells in the extended-interval group
were measured 3 weeks after the third and fourth immunizations, times close to
expected peak responses, whereas Env-specific B cells in all other vaccine groups were
measured 8 weeks after the third immunization.
TFH cell IL-4 secretion in lymph nodes and spleen. T follicular helper (TFH) cells
play an indispensable role in the activation of B cells and the production of high-affinity
antibodies. Specifically, interleukin-4 (IL-4) production can drive B cell proliferation and
class switching. Therefore, we determined the frequencies of TFH cells, as well as their
capacity to secrete IL-4, and tested for a correlation between TFH cells and HIV
Env-specific B cell responses.
In both the oral lymph nodes and spleens, TFH frequencies at necropsy were similar
in all animals independent of the vaccine regimen (Fig. 7A). However, the vaccine
regimens differentially affected the in vitro function of TFH cells. The Env protein group
had higher frequencies of IL-4-producing (IL-4) TFH cells in oral lymph nodes than
animals in the coadministration and prime/boost groups (Fig. 7B). Similarly, animals
receiving the Env protein vaccine regimen also had higher frequencies of IL-4-
producing TFH cells in the spleen than the prime/boost cohort (Fig. 7B). The extended-
interval group had lower TFH frequencies in the spleen than the accelerated coadmin-
istration group; however, both in spleens and in lymph nodes, the frequencies of
IL-4-producing TFH cells in animals receiving the coadministration vaccine were higher
in the extended-interval than in the accelerated group (Fig. 7A and B).
To further examine the importance of IL-4-producing TFH cells for HIV Env-specific
antibody function, we tested for correlations between IL-4 TFH cells and antibody
avidity, neutralizing antibodies, and ADCC activity. In spleens and in oral LNs, there
were positive correlations between the frequencies of IL-4-producing TFH cells and the
avidity indices of C.1086-specific plasma IgG (Fig. 7C); a similar correlation was not
observed when we applied the avidity score (P  0.23; data not shown). We also
observed a positive correlation between IL-4-producing TFH cells in tissues and maxi-
mum tier 1 neutralizing plasma antibodies (Fig. 7D). Consistent with the correlation
between the C.1086 gp120 avidity indices and ADCC activities measured using
SHIV1157ipd3N4 gp120 (Fig. 5C) and the correlation between avidity indices and
IL-4-positive TFH cells (Fig. 7C), there was also a positive correlation between
IL-4-producing TFH cells and ADCC activities measured using SHIV1157ipd3N4
gp120 (Fig. 7E).
SIV Gag and HIV Env-specific T cell responses in mesenteric lymph nodes.
Should a vaccine not be able to protect against infection, virus-specific T cell responses
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FIG 6 Tissue HIV Env-specific B cells. (A and B) HIV gp120-specific B cell frequencies in spleens (A) and oral lymph nodes (B) at necropsy were
determined by flow cytometry, and the results are reported as percentages of total CD20 B cells or as percentages of memory CD20 CD27
(Continued on next page)
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are essential to control early virus replication, thereby reducing virus dissemination and
the size of the viral reservoir. All vaccine regimens were able to induce SIV Gag-specific
CD4 and CD8 T cell responses in mesenteric LNs (Fig. 8A). The responses did not
differ in magnitude or cytokine profile between the 3 groups receiving an accelerated
vaccine regimen or between the groups receiving the accelerated and extended-
interval coadministration regimens. Similar data were obtained when we measured HIV
Env-specific CD4 and CD8 T cell responses in mesenteric LNs (Fig. 8B).
DISCUSSION
Based on the antibody responses associated with protection in the RV144 trial and
the short window of time that infants have to induce immunity before exposure and
potential HIV infection occur (8, 15), the goal of the current study was to identify a
pediatric vaccine regimen that could induce durable high concentrations of HIV
Env-specific antibodies with robust ADCC in plasma, in addition to eliciting Env-specific
mucosal IgA responses in the gastrointestinal tract. We compared three accelerated
regimens (3-week intervals), all beginning during the first week of life, to determine
which would produce the greatest magnitude and/or functional capacity of HIV Env-
specific plasma IgG. All vaccine regimens induced Env-specific plasma IgG in infant
macaques. However, antibody function differed depending on the regimen, as sum-
marized in Table 1.
High concentrations of consensus C gp120-specific plasma IgG with similar cross-
clade reactivities were observed in all groups that received the accelerated vaccina-
tions. These results are consistent with our previous pediatric SIV vaccine studies
documenting the induction of plasma IgG by accelerated vaccine regimens in infant
macaques (20, 29, 33, 34). In contrast, mucosal IgA responses were not or only poorly
induced by these 3 accelerated vaccine strategies.
In vaccine studies with adult macaques, the avidities of anti-Env serum IgG mea-
sured by NaSCN displacement ELISA have been correlated with the levels of ADCC
activity (35) and protection against rectal or vaginal SHIV or SIV challenge (30, 31, 36,
37). In the current study, the avidity indices of C.1086 gp120-specific IgG measured in
the NaSCN ELISA did not show evidence of differences between groups. However,
using SPR, the Env protein vaccine regimen was found to have induced antibodies with
significantly higher avidity to both C.1086 and CH505 gp120 than the prime/boost
regimen. The different results obtained in these avidity assays may reflect differential
induction of conformational and linear antibodies in the vaccine groups. It has been
reported that the results of NaSCN avidity assays primarily reflect antibodies to linear
epitopes, because chaotropic agents disrupt some conformational epitopes (38). Inter-
estingly, antibody avidities measured in the NaSCN assay correlated better overall with
ADCC activities. However, this does not mean that all ADCC antibodies generated in
these animals were directed against linear gp120 epitopes. Conformational antibodies
to the V3 loop have been found to survive urea treatment (38). As anti-V3 antibodies
dominated the response to gp120 in all vaccine groups, these antibodies may have
contributed to the ADCC activity in plasma. In the correlates analyses of the RV144 trial,
serum IgG1 and IgG3 binding antibodies directed to the V1V2 regions of gp120, as well
as serum antibodies mediating ADCC, were associated with reduced HIV acquisition (13,
14, 39). In this study, independent of the vaccine regimen, animals in all groups
developed plasma ADCC antibodies to the C.1086 gp120 immunogen. Although we did
not define ADCC epitope specificity, responses to V1V2 and C1 epitopes associated with
ADCC-mediated protection in the RV144 trial were elicited in all vaccine groups (13, 14).
FIG 6 Legend (Continued)
B cells. (C) HIV Env-specific B cell frequencies in tissues of animals in the extended-interval group. (D) Representative fluorescence-activated
cell sorting (FACS) plot of gp120-specific B cells in the colon of an animal in the extended-interval group. Background staining in an
unvaccinated control animal is shown for comparison. Reported values for total and memory B cells specific for HIV gp120 were corrected for
nonspecific staining in control samples. (E) Frequencies of HIV Env gp120-specific total CD20 B cells and memory CD20 CD27 B cells in
the colons of vaccinated infant macaques. The symbols are as defined in the keys in Fig. 2A and 3A.
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FIG 7 T follicular helper (TFH) cell frequency and function. (A) The TFH cell frequencies in animals of the various vaccine
groups are reported as CXCR5 PD-1high T cells within the population of CD95 CCR7low CD4 T cells in oral lymph nodes
(Continued on next page)
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In addition, we found clear differences among groups when we measured tier 1
neutralizing antibodies to the clade C virus MW965. The prime/boost group showed
delayed antibody kinetics and lower titers compared to those in the groups receiving
the other accelerated regimens, whereas the Env protein regimen gave the highest and
longest lasting responses.
Despite similar plasma levels of Env-specific IgG, the Env-specific B cell frequencies
in spleens and oral LNs differed between the 3 accelerated vaccine regimens. Overall,
Env-specific B cell frequencies were lower in spleens than in oral LNs. In the prime/
boost group, only 1 of 5 infant macaques had detectable Env-specific B cells in oral LNs,
whereas Env-specific B cells could be detected in all animals of the Env protein and
FIG 7 Legend (Continued)
or spleens. (B) The function of TFH cells was assessed as percentages of TFH cells producing IL-4 after in vitro stimulation.
(C to E) Spearman’s rank test correlations between frequencies of IL-4-producing TFH cells in spleens or oral lymph nodes
and plasma gp120-IgG avidities (C), maximum tier 1 plasma neutralizing antibodies (D), and levels of ADCC granzyme
B activity directed against SHIV1157ipd3N4 (E) are shown. The symbols are as defined in the keys in Fig. 2A and 3A.
FIG 8 SIV Gag-specific and HIV Env-specific T cell responses. (A and B) Percentages of SIV Gag or HIV Env-specific CD4 (left) and CD8 T cells (right) in
mesenteric LNs. Each bar represents the sum of the mean frequencies  SEM of IFN-, IL-2, IL-17, or TNF- single-positive T cells in each group.
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coadministration groups. Although we did not determine antigen specificity, animals in
the coadministration group also had a slightly higher median plasmablast frequency in
the bone marrow. As described in “Statistical analysis” below, a studywise false discov-
ery rate was utilized to account for multiple comparisons; for this false discovery rate
(0.05), none of the null hypotheses tested in this paper would be rejected. Therefore,
the reported unadjusted P values should be interpreted cautiously.
Among the accelerated vaccine regimens, vaccine-induced antibody breadth and
function were lowest in the prime/boost group. The results for the Env protein strategy
seemed to be slightly superior to the results for the coadministration group with regard
to antibody avidity and tier 1 neutralization capacity. The finding that Env protein
immunization can induce functional antibody responses in infant macaques is in
agreement with data from studies by Fouda et al. (19), who showed in a retrospective
analysis that the majority of human infants vaccinated with an MF59-adjuvanted gp120
protein vaccine maintained detectable plasma antibodies up to 1 year after their last
immunization. Determining whether these antibodies can prevent oral virus transmis-
sion and which avidity assay best predicts protection need to be addressed in future
vaccine/challenge studies with infant macaques. In human clinical HIV-1 vaccine trials
in adults, strategies utilizing only Env protein did not elicit protection (40, 41).
Therefore, we decided to compare the accelerated coadministration regimen, which
had also elicited some immune correlates of protection identified in the RV144 trial, to
an extended-interval coadministration regimen. The peak plasma IgG did not differ
between these two groups, but by testing an extended-interval group, we have shown
antibody persistence up to 20 weeks after the last immunization, as well as the
generation of Env-specific memory B cells that could be activated by a boost at this
time. The plasma Env-specific IgG in the extended-interval group showed avidity
TABLE 1 Summary of vaccine-induced immune responses
Parameter
Response to indicated vaccine regimen
Accelerated interval
Extended interval
coadmininistration
Env
protein
Prime/
boost Coadministration
Plasma IgG
Magnitude    
Breadth    
Epitope recognition
Magnitude    
Breadth    
Bone marrow plasmablasts    
Mucosal IgA / / / 
Avidity    
ADCC    
Tier 1 neutralizing antibody    
gp120-specific B cells
Spleen    
LNs    
Colon / / / 
TFH cells
Frequency    
Function    
SIV Gag-specific T cells
Frequency    
Function    
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superior to that of such antibodies in the accelerated coadministration regimen.
Furthermore, while animals in both groups developed plasma ADCC antibodies to the
C.1086 gp120 immunogen, the median granzyme B activity against the heterologous
SHIV1157idp3N4 Env was higher in infant macaques given the extended-interval
regimen.
In addition, the extended-interval regimen, but not the accelerated coadministration
regimen, also induced gp120-specific IgA responses in the gastrointestinal tract, sug-
gesting that the development of intestinal IgA responses in infants may be optimal if
vaccinations are performed at 6-week rather than 3-week intervals. We have previously
shown that oral vaccine priming followed by systemic boosting in infants generates
salivary or intestinal IgA responses that, albeit not protective against infection, correlate
with control of viremia after oral SIV exposure (20, 29). Similarly, vaccine-mediated
induction of Env-specific mucosal IgA responses at sites of SIV or SHIV challenge has
been associated with protection, delayed rates of infection, or control of viremia in
adult macaques (30, 36, 37, 42). Consistent with the induction of mucosal gp120-
specific IgA, gp120-specific B cells in intestinal tissues were only detected in the
extended-interval group. The detection of these cells was not simply due to a longer
follow-up period after immunization, because Env-specific B cells in the colon were
already detectable at week 15. Oral lymph nodes collected at the time of euthanasia in
the extended-interval group had relatively low frequencies of Env-specific B cells (data
not shown; median value, 0.1% of total B cells), but splenic Env-specific B cells were
found at higher frequencies (median values, 0.45% of B cells and 1.5% of CD27 B cells).
The CD4 or CD8 T cell responses to HIV Env or SIV Gag did not differ between the
groups. The observed SIV Gag-specific T cell responses were similar in magnitude and
function to those observed in previously described accelerated prime/boost pediatric
vaccine strategies (23, 29, 34). With the caveat that T cell responses were only analyzed
at the time of euthanasia and only in mesenteric LNs, the extension of the immuniza-
tion interval from 3 to 6 weeks did not appear to improve SIV Gag-specific or HIV
Env-specific T cell responses.
In contrast, differences in vaccine-induced TFH function resulting from the distinct
vaccine regimens were associated with differences in vaccine-induced antibody re-
sponses, both in magnitude and in function. Thus, the frequency of IL-4-producing TFH
cells in tissues was predictive of gp120-specific plasma IgG avidity, maximum neutral-
izing tier plasma antibodies, and ADCC activity against heterologous SHIV1157ipd3N4,
and animals with lower IL-4-producing TFH cell frequencies also exhibited lower levels
of plasma antibody function. Elucidating the enhancement of TFH function via different
vaccine regimens will be an important question to solve in order to develop an effective
pediatric HIV vaccine.
Taken together, these data suggest that the dynamics of B cell and antibody
circulation can be affected by the vaccine regimen and the vaccine interval. Acknowl-
edging the caveat of relatively small group sizes, few studies have compared different
vaccine regimens side-by-side in infants (43). Overall, the extended-interval regimen
induced superior functional responses, such as broader ADCC activity and stronger
intestinal IgA responses. The critical question remains as to whether these Env-specific
antibody responses can prevent oral acquisition of immunodeficiency virus. An
extended-interval regimen may be less efficient in protecting infants in the early
postnatal phase. However, protection during this early risk period might be achieved
through the administration of broadly neutralizing monoclonal antibodies (44) or
long-acting antiretroviral drug formulations (45) shortly after birth. Thus, the vaccine
regimen could potentially be tailored to fit the local availability of other early inter-
ventions and the expected duration of breastfeeding. In addition, the ability of a
pediatric HIV vaccine to elicit persistent antiviral immune responses, as shown in the
current study, would not only have the potential to protect against breast milk
transmission of HIV but might provide protection into adulthood if a vaccine boost was
given in early adolescence prior to sexual activity.
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MATERIALS AND METHODS
Vaccine preparation. A recombinant modified vaccinia virus Ankara (MVA) (A711) expressing the
HIV Env C.1086 gp120 protein (corresponding to residues 1 to 497 with a deletion of 6 amino acids
[TVYYGV] and the mutation of K to N at position 160 [K160N]) was constructed as described previously
for the construction of the gp140-expressing MVA virus A703 (46). Recombinant MVA expressing gp120
was cultured in BHK-21 cells and then partially purified by ultracentrifugation through 36% sucrose
cushions as described previously (47). Monoclonal antibodies (VRC C 16H3) were used in Western blot
analyses of proteins extracted from A711-infected BHK-21 cells to confirm the expression of the gp120
protein. The recombinant MVA expressing SIVmac239gag-pol was designed as described previously (46,
48). The recombinant C.1086_D7gp120K160N gp120 Env protein was produced in 293T cells as described
previously (46).
Animals. Twenty SIV- and type D retrovirus-negative newborn Indian-origin rhesus macaques
(Macaca mulatta) were hand reared in the nursery of the California National Primate Research Center
(CNPRC, Davis, CA) in accordance with the American Association for Accreditation of Laboratory Animal
Care standards. The Guide for the Care and Use of Laboratory Animals of the Institute for Laboratory
Animal Research, National Research Council (49), and the International Guiding Principles for Biomedical
Research Involving Animals (50) were strictly adhered to. All protocols were reviewed and approved by
the University of California at Davis Institutional Animal Care and Use Committee prior to the initiation
of the study. Animals were randomly assigned to the various groups between 3 and 7 days of age, when
the first immunization was administered. For both vaccinations and sample collection, animals were
anesthetized with 10 mg/kg of body weight of ketamine-HCl via the intramuscular (i.m.) route (Parke-
Davis, Morris Plains, NJ).
Animal immunization regimens. As outlined in Fig. 1, infant macaques in the Env protein, prime/
boost, and coadministration groups received immunizations at 0, 3, and 6 weeks of age. Infant macaques
in all groups received MVA-SIVgag/pol i.m. (5 	 108 infectious units [IU] in 0.25 ml, split between
quadriceps muscles) at every immunization time point to induce cellular immune responses, with the
goal of limiting virus replication and dissemination. However, as our main goal was to induce functional
ADCC-mediating HIV Env-specific antibody responses, the nomenclature of the group assignments was
based on the various regimens used to elicit HIV Env-specific antibody responses. Infants in the Env
protein group (n  5) were vaccinated with C.1086 gp120 by both the i.m. (15 g in 0.25 ml split
between both gluteus muscles) and the i.n. (200 g in 0.15 ml given dropwise with 30 s between drops
and 3 drops per nostril) route. The i.m. protein immunizations contained 15 g of Span85-Tween
80-squalene (STS) adjuvant as described previously (51), whereas Env protein by the i.n. route was given
with 200 g of the Toll-like receptor 7 and 8 (TLR7/8) agonist R848 (51). To enhance the induction of
Env-specific antibody responses, infant macaques in the prime/boost group (n  5) were primed i.m.
with MVA-HIV Env at week 0 (5 	 108 IU in 0.25 ml split between the quadriceps) and then given C.1086
gp120 boosts at weeks 3 and 6. The coadministration group (n  5) was vaccinated with both the
MVA-HIV Env vector and the gp120 protein at weeks 0, 3, and 6. Animals were followed for 15 to 19
weeks, when they were euthanized to analyze vaccine-induced tissue responses. In addition, we
included a group of infant macaques that received the same vaccine regimen as the coadministra-
tion group, but the immunization intervals were extended to 6 weeks (extended-interval group; n 
5). At week 32, infant macaques in the extended-interval group received a final boost, before being
euthanized at week 35.
Collection and processing of blood and tissue specimens. Blood, saliva, and stool samples were
collected before each immunization and then biweekly throughout the study. Saliva was collected with
Merocel sponges (Beaver-Visitec, Waltham, MA), which were immediately snap-frozen. For stool collec-
tion, 2 to 3 g of fresh stool was added to 0.5% bovine serum albumin (BSA) in 5 ml sterile phosphate-
buffered saline (PBS) supplemented with 1% protease inhibitor cocktail (product number P8340; Sigma).
Saliva and stool samples were stored at 80°C.
Whole blood was collected, and plasma was obtained by centrifugation and stored at 80°C;
peripheral blood mononuclear cells (PBMCs) were isolated as described previously (20, 29). At euthanasia,
spleens, lymph nodes (LNs; axillary, mesenteric, submandibular, cervical, submental, and retropharyn-
geal), and intestinal tissues (colon and ileum) were collected and mononuclear cell (MNC) suspensions
were prepared as described previously (20, 29).
At week 15, colon and axillary LN biopsy specimens were collected from animals of the extended-
interval group. Prior to colonoscopy, animals were fasted for approximately 24 h. The morning of the
procedure, the animals were sedated with ketamine and, if necessary, dexmedetomidine. Next, 30 ml/kg
of a gastrointestinal lavage solution (GoLytely [Braintree Laboratories, Braintree, MA]; prepared by mixing
with 1 liter of citrus-flavored water or Kool-Aid [Kraft Foods, Inc.]) was administered via naso- or
orogastric tube. The remaining GoLytely solution was made available for the animal to drink. If the
remaining solution was not consumed, the animal was sedated a second time (approximately 6 h later)
to administer a second dose of GoLytely at 30 ml/kg to ensure that a total of 60 ml/kg was ingested. The
use of GoLytely is important to get proper cleansing of the colon, without which there is more risk for
perforation of the intestinal wall due to poor visibility (52). Animals were anesthetized with ketamine and
dexmedetomidine during the colonoscopy procedure and monitored throughout the procedure by
standard surgical monitoring (pulse, oximeter, and vitals check). The ultraslim pediatric endoscope
(model number EG-1690K; Pentax Medical Company, Montvale, NJ) was lubricated, inserted into the
rectum, and slowly advanced approximately 5 to 15 cm into the colon, depending on the animal’s size.
The left splenic flexure and right hepatic flexure were used to navigate to the proximal ascending colon.
By performing proximal colonoscopy, we had access to a vast area (up to approximately 30 cm2) of the
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proximal and transverse colon to collect 5 to 8 pinch biopsy specimens. Animals were monitored until
recovery from anesthesia and postoperatively for a minimum of 5 days. They also received ketoprofen
at 2 mg/kg i.m. once daily for 3 days.
Purification of Rhesus IgG by affinity chromatography. A pool of IgG purified from plasma of two
adult rhesus macaques previously vaccinated with HIV Env protein (RIVIG) (46) was used as the standard
in the binding antibody multiplex assay (BAMA). IgG purification was performed as described previously
(53). The total IgG concentration was determined by measuring absorbance at 280 nm with a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific).
BAMA for antibodies in plasma. BAMA was performed as described previously (54–59). Briefly, HIV
antigens were conjugated to polystyrene beads (Bio-Rad) and the binding of plasma IgG to the
bead-conjugated HIV antigens was measured. Positive controls included pooled purified IgG from
HIV-positive persons (HIVIG; NIH AIDS Reagent Program), RIVIG, and a simian version of the HIV-specific
human IgG neutralizing antibody b12 (B12R1). Beads and diluted plasma were incubated, and then
bound IgG was detected using either a phycoerythrin (PE)-conjugated mouse anti-monkey IgG (Southern
Biotech) at 4 g/ml for macaque plasma, B12R1, and RIVIG or a PE-conjugated mouse anti-human IgG
(Southern Biotech) at 2 g/ml for HIVIG. The beads were washed and acquired on a Bio-Plex 200
instrument (Bio-Rad). IgG binding was expressed as mean fluorescence intensity (MFI). To control for
nonspecific binding, the MFI of sample binding to unconjugated blank beads was subtracted from the
MFI of each antigen. An HIV-specific antibody response was considered positive if it had MFI values
above both (i) the mean MFI of preimmunized plasma samples at week 0  3 standard deviations (SD)
and (ii) the lower detection limit of 100 MFI. The 50% effective concentrations (EC50) and maximum MFI
values of the standards (B12R1, HIVIG, and RIVIG) were tracked by Levy-Jennings charts to ensure
consistency between assays.
Measurement of HIV Env-specific antibodies by ELISA. The plasma concentrations of HIV Env-
specific antibodies were determined by ELISA (60). The 384-well plates were coated with 3 g/ml of
consensus C gp120 overnight at 4°C and then blocked with superblock (PBS plus 4% whey, 15% normal
goat serum, and 0.5% Tween 20). After washing, serially diluted plasma was added to the plates. IgG were
detected with peroxidase-labeled anti-monkey IgG (Southern Biotech), followed by tetramethylbenzidine
(TMB; KPL) and stop solution. Immediately after the addition of the stop solution, absorbance was read
at 450 nm. B12R1 was used as the standard (60). The concentration of HIV Env-specific IgG relative to the
standard was calculated with a five-parameter fit curve using SoftMax Pro 6.3 software (Molecular
Devices). To account for nonspecific binding, the positivity cutoff was selected as the concentration
corresponding to 3 times the optical density (OD) of blank wells.
Plasma antibody linear epitope mapping. Plasma IgG linear epitope mapping by peptide microar-
ray was performed as previously described (55, 61, 62) with minor modifications. Array slides were
provided by JPT Peptide Technologies GmbH (Germany) by printing a library designed by B. Korber (Los
Alamos National Laboratory) onto epoxy glass slides (PolyAn GmbH, Germany). The library contains
overlapping peptides (15-mers overlapping by 12) covering 6 full-length gp160 consensus sequences
(clades A, B, C, and D, group M, CRF1, and CRF2) and the gp120 sequences of 6 vaccine strains (MN, A244,
Th023, TV-1, ZM651, and C.1086). Three identical subarrays, each containing the full peptide library, were
printed on each slide. All array slides were blocked for 1 h, followed by 2 h of incubation with serum
samples diluted 1:50 and a subsequent 45 min of incubation with goat anti-human IgG conjugated to
Alexa Fluor 647 (AF647; Jackson ImmunoResearch, PA). The array slides were scanned at a wavelength
of 635 nm with an InnoScan 710 scanner (Innopsys, Carbonne, France) using the extended dynamic
range (XDR) mode. Images were analyzed using MagPix 7.4.1 software (Luminex Corporation) to obtain
binding intensity values for all peptides. The binding values for preimmune serum from each animal were
subtracted from the postimmunization binding values for each peptide. The binding magnitude to each
epitope was defined as the highest binding to a single peptide within the epitope region.
BAMA for mucosal antibodies. Salivary and fecal antibodies to C.1086 gp120 were measured using
BAMA. The gp120 protein (50 g) was conjugated to 1 	 107 Bio-Plex magnetic beads (Bio-Rad) as
described previously (63). Test samples were depleted of IgG using protein G-Sepharose. White microtiter
plates previously blocked with PBS, containing 1% BSA, 0.05% Tween 20, and 0.05% azide (bead buffer),
were loaded with 25 l beads plus 25 l diluted standard or mucosal fluid that had been clarified by
centrifugation at 18,000 	 g for 5 min. The standard was IgA or IgG that had been purified from serum
of SHIV-infected macaques using peptide M agarose (Invivogen) or protein G-Sepharose (Genscript). The
concentrations of the standards were adjusted so that they produced results analogous to those
obtained in ELISA with plasma samples. The plate was mixed overnight at 4°C on an orbital shaker. The
following day, the beads were washed with PBS containing 0.05% Tween 20, mixed for 30 min with bead
buffer containing 2 g/ml biotinylated goat anti-monkey IgA or IgG (Rockland Immunochemicals),
washed, and mixed with 1/400 phycoerythrin-labeled Neutralite avidin for 30 min (Southern Biotech).
After a final wash, the beads were resuspended in 100 l of bead buffer and analyzed in a Bioplex 200
using Bioplex Manager software (Bio-Rad). To obtain specific activities, the concentrations of antibody
were divided by the total IgA in the samples. Total IgA or IgG concentrations were measured by ELISA
as described previously (64).
Avidity assays. The avidities of anti-C.1086 gp120 plasma IgG were measured using a sodium
thiocyanate (NaSCN) displacement ELISA (20) and surface plasmon resonance (SPR). Briefly, for the
NaSCN ELISA, plates coated with 100 ng per well of C.1086 gp120 were reacted overnight with the
standard and plasma samples on two sides of the plate. The following day, wells on one side of the plate
were treated with 1.5 M NaSCN for 10 min at 37°C. The plates were then developed using biotinylated
affinity-purified goat anti-monkey IgG (Rockland Immunochemicals), neutralite avidin-peroxidase, and
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TMB (SouthernBiotech). The avidity indices (AI) were calculated by dividing the concentrations of
antibody in NaSCN-treated wells by the concentrations in untreated wells.
Surface plasmon resonance measurements of purified plasma IgG avidity were performed using a
Biacore 4000 instrument (GE Healthcare). Using a multiplex array format (2 by 8), binding responses were
measured by SPR in duplicate following immobilization by amine coupling of envelope protein (15) or
capture of biotinylated antigens to immobilized streptavidin on series S CM5 sensor chips. Purified
plasma IgG samples at 150 g/ml (except for animal 45038, whose sample was used at 75 g/ml due to
insufficient IgG) were flowed (2.5 min) over duplicate spots of antigen, followed by a dissociation phase
(postinjection/buffer wash) of 10 min. Nonspecific binding of a preimmune (time zero) sample was
subtracted from the binding data for each postimmunization IgG sample. Data analyses were performed
with BIAevaluation 4000 and BIAevaluation 4.1 software (BIAcore/GE Healthcare). Binding responses were
measured by averaging postinjection response units (RU) over a 10-s window, and the dissociation rate
constants (Kd [s1]) were measured during the postinjection phase (after stabilization of the signal). A
positive response was defined when the RU was 10. The relative avidity binding score was calculated
as follows: avidity score (RUs)  (binding RUs/Kd).
Neutralization assays. Neutralization of tier 1 and tier 2 clade C viruses by plasma was measured in
TZM-bl cells by the reduction in luciferase reporter gene expression after a single round of infection, as
described previously (65). Neutralization was assessed using MW965.LucR.T2A.ecto/293T (tier 1) and
C.1086_B2.LucR.T2A.ecto/293T (tier 2) infectious molecular clones (IMCs). Broadly neutralizing antibody
B12R1 or VRC01 was used as a positive control. The 50% inhibitory dose (ID50) was calculated as the
plasma dilution or antibody concentration that caused a 50% reduction in relative light units (RLUs)
compared to the RLUs in the virus control wells after subtraction of cell control RLUs. The preimmuni-
zation time point (week 0) was used to measure background levels of neutralization.
Plasmablast analysis. Bone marrow cell suspensions were stained according to the protocol
developed for rhesus macaques by Silveira et al. (66). Briefly, cells were stained for surface expression of
CD3-PE-CF594, CD14-PE-CF594, CD16-PE-CF594, CD20-allophycocyanin (APC)-H7, CD11c-PE, CD123-PE,
CD80-BUV395, and HLA-DR-BV711, with IgG-V450 (surface IgG [sIgG]), and for intracellular expression of
Ki-67–fluorescein isothiocyanate (FITC) and IgG-AF700 (immune complex of IgG [ICIgG]). All antibodies
were obtained from BD Biosciences. A live/dead discriminator dye was included in all panels. Samples
(500,000 events) were acquired on a BD LSRFortessa instrument and analyzed using FlowJo software
version 10 (TreeStar, Ashland, OR). Plasmablasts were defined as being negative for the lineage marker
(CD3, CD14, and CD16), the dendritic cell markers CD11c and CD123, and sIgG but positive for HLA-DR
(HLA-DR), Ki-67 (Ki-67), and ICIgG (ICIgG). Plasmablasts exhibited no or only intermediate expression
of CD20 (CD20/int). In contrast to previous studies enumerating plasmablasts in PBMCs (66, 67), the
bone marrow plasmablasts did not express CD80.
Detection of HIV Env-specific B cells. PBMCs and tissue MNC suspensions were treated with 5 M
Chk2 inhibitor II {2-[4-(4-chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide; Sigma} and 1% BSA
(Sigma) and blocked with 6.25 g/ml anti-human CD4 antibody (BD) at 4°C for 15 min. We then costained
cells with custom-conjugated BV421-gp120 (C.1086) and AF647-gp120 (C.1086) prepared as described
previously (68). Paraformaldehyde-fixed samples were acquired on a BD LSRII Fortessa instrument and
analyzed using FlowJo software version 10 (Tree Star, Ashland, OR). The following gating strategy was
applied: lymphocytes were gated on singlets and live cells were selected to gate on CD3 cells (T cells),
CD14 cells (monocytes/macrophages), or CD20 cells (B cells). B cells were further gated on CD27
memory B cells. Only B cells positive for both BV421-gp120 and AF647-gp120 were considered HIV Env
specific, and these populations were normalized against data from nonimmunized control animals.
T follicular helper (TFH) cell analysis. Tissue MNC suspensions containing 1.5 	 106 to 3.0 	 106
cells were resuspended in complete RPMI 1640 containing 0.5 g/ml anti-CD28 antibody and 0.5 g/ml
anti-CD49d antibody (BD Biosciences). Cells were treated with 0.5	 cell stimulation cocktail (eBioscience)
or medium only and cultured for 6 h (37°C and 5% CO2), with the addition of 1	 brefeldin A (eBioscience)
after the first hour. Cells were stained, and paraformaldehyde-fixed samples were acquired as described
above. Gating was based on a lymphocyte gate, followed by gating on singlets and then live cells. CD3
CD4 T cells were further gated on CD95 CCR7low cells. TFH cells were defined as PD-1high CXCR5 cells
within the population of CD95 CCR7low CD4 T cells. Gates were based on fluorescence-minus-one
(FMO) controls, and all cytokine analyses were performed after Boolean gating.
SIV Gag and HIV Env-specific T cell responses. Mesenteric LN cell suspensions were stimulated
with 10 g/2 	 106 cells of SIV Gag or HIV Env peptide pools (NIH Reference and Reagent Program) for
6 h, with brefeldin A being added for the last 5 h. Negative- and positive-control cultures included
medium only or cell stimulation cocktail, respectively. Cells were stained as previously described (20, 34,
69), and 300,000 events were acquired on an LSRII Fortessa instrument and analyzed using FlowJo
version 10 software. Gates were based on FMO controls, and cytokine analyses were performed after
Boolean gating. The frequencies of gamma interferon (IFN-), IL-2, IL-17, and tumor necrosis factor alpha
(TNF-) single-positive CD4 or CD8 T cells are reported after subtracting background values obtained
in medium-only cultures.
ADCC assay. The GranToxiLux (GTL) assay was used to detect plasma ADCC activity directed against
CCR5 CEM.NKR T cells (AIDS Reagent Program; contributed by Alexandra Trkola) coated with the C.1086
gp120 or clade C SHIV1157ipd3N4 gp120 as described previously (70). ADCC activity was measured in
4-fold serial plasma dilutions starting at 1:100. Cryopreserved human PBMCs from an HIV-seronegative
donor with the 158F/V genotype for FcRIIIa were used as the source of effector cells (71). Data were
reported as the proportion of cells positive for proteolytically active granzyme B out of the total viable
target cell population after subtracting the background activity observed in wells containing effector and
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target cells in the absence of plasma. ADCC endpoint titers were determined by interpolating the
dilutions of plasma that intercept the positive cutoff.
Statistical analysis. Pairwise comparisons of assay measurements were performed among the four
vaccination groups using Wilcoxon rank-sum tests with exact P values. Comparisons were performed
between groups with the same vaccine interval (Env protein, prime/boost, and coadministration groups)
or between groups with the same vaccine regimen but different vaccine intervals (coadministration and
extended interval). Spearman’s rank correlation coefficients were calculated and tested with exact P
values where indicated (Fig. 4 and 7). All statistical analyses were two-tailed, and the P values reported
were not adjusted for multiple comparisons. The Benjamini-Hochberg step-up procedure was used to
determine if any null hypotheses would be rejected for a studywise false discovery rate of 0.05 (72). Data
were stored and managed using REDCap, hosted at the Duke University Office of Clinical Research,
analysis was performed using SAS 9.3 (SAS Institute, Cary NC), and graphs were created using GraphPad
Prism software (version 6; GraphPad, Inc., La Jolla, CA).
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